Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 15 de 15
Filtrar
Más filtros

Medicinas Complementárias
Bases de datos
País/Región como asunto
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
J Clin Hypertens (Greenwich) ; 25(9): 880-888, 2023 09.
Artículo en Inglés | MEDLINE | ID: mdl-37608640

RESUMEN

Atherosclerosis is associated with various cardiovascular diseases (CVDs). Measurement of arterial stiffness using pulse wave velocity (PWV) enables assessment of atherosclerosis progression in individuals. The authors screened patients with asymptomatic atherosclerosis, based on the PWV findings, to evaluate appropriate early interventions and assess the efficacy of γ-linolenic acid, Vitis vinifera extract, and acetyl-L-carnitine triple combination therapy in atherosclerosis prevention. This retrospective study analyzed the medical records of adult patients between March 2007 and April 2019, with presenting complaints of fatigue and lethargy. Among patients with vascular stiffness beyond their biological age on brachial-ankle PWV (baPWV) testing, those with ≥80% compliance for three drugs were allocated to the experimental group. Those with compliance of <80% for any one drug were allocated to the control group to assess changes in arterial stiffness, fasting plasma glucose (FPG), lipid level, and blood pressure (BP). After 1 year of triple-combination therapy, there were significant decreases in right and left baPWV (1537.16 ± 274.84 and 1519.00 ± 289.32 cm/s, respectively) as compared to baseline (1633.15 ± 271. 20 and 1598.64 ± 267.95 cm/s, respectively; p < .001). There was no difference in baPWV between sexes. Moreover, neither group showed significant changes in FPG and lipid levels. When triple-combination therapy combining γ-linolenic acid, V. vinifera extract, and acetyl-L-carnitine was administered to patients with high arterial stiffness relative to their age, as assessed by baPWV, the experimental group showed a decrease in arterial stiffness in both sexes.


Asunto(s)
Aterosclerosis , Hipertensión , Rigidez Vascular , Vitis , Femenino , Masculino , Humanos , Adulto , Acetilcarnitina , Ácido gammalinolénico/uso terapéutico , Análisis de la Onda del Pulso , Estudios Retrospectivos , Extractos Vegetales/uso terapéutico , República de Corea/epidemiología
2.
BMC Complement Med Ther ; 20(1): 297, 2020 Oct 06.
Artículo en Inglés | MEDLINE | ID: mdl-33023584

RESUMEN

BACKGROUND: Citrus sunki Hort. ex Tanaka peel has been traditionally used as an ingredient in folk medicine due to its therapeutic effects on promotion of splenic health and diuresis as well as relief of gastrointestinal symptoms. Although a growing interest in health-promoting natural products and the development of highly concentrated products have facilitated consumption of C. sunki peel, its safety assessment has not been explored, posing a potential health risk. In this study, we carried out a series of systemic and genetic toxicity tests on fermented C. sunki peel extract (FCPE) to provide the essential information required for safe use in human. METHODS: We conducted acute and 90-day repeated oral toxicity studies in Sprague-Dawley rats to evaluate systemic toxicity, and three genotoxicity assays to measure bacterial mutation reversion, cellular chromosome aberration and in vivo micronucleus formation. RESULTS: Single oral administration of FCPE did not cause any clinical signs and lethality in all animals, establishing LD50 to be over 2000 mg/kg BW. Repeated administration of up to 2000 mg/kg BW FCPE for 90 days revealed no test substance-related toxicity as demonstrated in analysis of body weight gain, food/water intake, blood, serum biochemistry, organ weight and histopathology, collectively determining that the no-observable-adverse-effect-level of FCPE is over 2000 mg/kg BW. In addition, we detected no mutagenicity and clastogenicity in FCPE at 5000 µg/plate for the in vitro assays and 2000 mg/kg BW for the in vivo micronucleus test. CONCLUSION: FCPE did not cause systemic and genetic toxicity in our model systems at the tested dose levels. These results suggest a guideline for safe consumption of C. sunki peel in human.


Asunto(s)
Citrus/toxicidad , Extractos Vegetales/toxicidad , Animales , Femenino , Alimentos Fermentados/toxicidad , Masculino , Pruebas de Mutagenicidad , Tamaño de los Órganos , Ratas , Ratas Sprague-Dawley , República de Corea , Pruebas de Toxicidad Aguda
3.
J Ethnopharmacol ; 238: 111874, 2019 Jun 28.
Artículo en Inglés | MEDLINE | ID: mdl-30986520

RESUMEN

ETHNOPHARMACOLOGY RELEVANCE: Dendropanax morbifera Leveille (DM) has been used in traditional medicines for infectious and skin diseases, and dysmenorrhea. It exhibits a diverse therapeutic potential including anti-cancer, anti-thrombotic, anti-diabetic, anti-oxidant, and anti-inflammatory activities. AIM OF THE STUDY: Despite promising health benefits of DM, knowledge of its potential adverse effects is very limited. The current study focused on the investigation of subchronic toxicity and genotoxicity of extract obtained from DM according to the test guidelines published by the Organization for Economic Cooperation and Development. MATERIALS AND METHODS: We conducted a toxicological evaluation of DM extracts using 14-day repeated-dose toxicity study and 13-week repeated-dose toxicity study in Sprague-Dawley rats administered orally at doses of 500, 1000, or 2000 mg/kg/day. The clastogenicity of DM extract was also evaluated by in vitro chromosome aberration assay and in vivo micronucleus assay. RESULTS: Assessment of subchronic toxicity of DM extract by oral administration in rats revealed unremarkable treatment-related findings with respect to food/water consumption, body weight, mortality, urinalysis, hematology, serum biochemistry, necropsy, organ weight and histopathology at doses of 500, 1000, and 2000 mg/kg. Accordingly, the level of no-observed-adverse-effect for DM extract in 13-week subchronic toxicity study was considered to be 2000 mg/kg/day in rats. The data observed from in vitro chromosome aberration assay and in vivo micronucleus assay exclude any clastogenicity of DM extract. CONCLUSION: The results suggest that the oral consumption of DM extract has no adverse effects in humans and represents a safe traditional medicine.


Asunto(s)
Aberraciones Cromosómicas/efectos de los fármacos , Magnoliopsida/química , Extractos Vegetales/toxicidad , Hojas de la Planta/química , Animales , Línea Celular , Cricetinae , Femenino , Fibroblastos/efectos de los fármacos , Masculino , Ratones , Ratones Endogámicos ICR , Pruebas de Mutagenicidad , Extractos Vegetales/química , Ratas , Ratas Sprague-Dawley
4.
J Headache Pain ; 20(1): 17, 2019 Feb 14.
Artículo en Inglés | MEDLINE | ID: mdl-30764752

RESUMEN

BACKGROUND: Headache disorder is not only a common complaint but also a global burden. Pharmacotherapeutic and non-pharmacotherapeutic approaches have been developed for its treatment and prophylaxis. The present study included a systematic review of psychological treatments for primary headache disorder accessible in Korea. METHODS: We included English and Korean articles from EMBASE, MEDLINE, Cochrane library database, SCOPUS, ScienceDirect, Web of Science, CINAHL, PsycArticles and Korean database, KoreaMed and KMBASE which studied primary headache and medication-overuse headache. The primary efficacy measure was the number of headache days per month, while secondary efficacy measures were the number of headache attacks per week, headache index, treatment response rate, and migraine disability assessment. The meta-analysis was performed using R 3.5.1. to obtain pooled mean difference and pooled relative risk with 95% confidence interval (CI) for continuous data and dichotomous data, respectively. RESULTS: From 12,773 identified articles, 27 randomized clinical trials were identified. Primary outcome showed significant superiority of psychological treatments (pooled mean difference = - 0.70, 95% CI [- 1.22, - 0.18]). For the secondary outcomes, the number of headache attacks (pooled mean difference = - 1.15, 95% CI [- 1.63, - 0.67]), the headache index (pooled mean difference = - 0.92, 95% CI [- 1.40 to - 0.44]) and the treatment response rate (pooled relative risk = 3.13, 95% CI [2.24, 4.37]) demonstrated significant improvements in the psychological treatment group over the control group. CONCLUSION: Psychological treatments for primary headache disorder reduced headache frequency and the headache index. Future research using standardized outcome measures and strategies for reducing bias is needed.


Asunto(s)
Cefaleas Primarias/psicología , Cefaleas Primarias/terapia , Psicoterapia , Humanos , Psicoterapia/métodos , Ensayos Clínicos Controlados Aleatorios como Asunto , Resultado del Tratamiento
5.
Regul Toxicol Pharmacol ; 95: 115-123, 2018 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-29501463

RESUMEN

Cinnamomum cassia has been widely used as a natural product to treat diseases in Asia due to its diverse pharmacological functions including anti-inflammatory, anti-oxidant, anti-microbial, anti-diabetic, and anti-tumor effects. Despite its ethnomedicinal benefits, little information regarding its toxicity is currently available. The aim of this study was to evaluate its potential long-term toxicity and genotoxicity in compliance with test guidelines of the Organization for Economic Cooperation and Development. A 13-week repeat-dose oral toxicity study revealed that body weights of rats were normal after receiving cinnamon extract at up to 2000 mg/kg. High-dose intake of cinnamon extract (2000 mg/kg) showed potential nephrotoxicity and hepatotoxicity to both males and females as evidenced by obvious increases of kidney/liver weight along with a small but statistically elevation of total cholesterol level. Overall findings from genetic toxicity testing battery including Ames test, in vitro mammalian cell micronucleus assay, and in vivo bone marrow micronucleus assay indicated that cinnamon extract was not mutagenic or clastogenic. In conclusion, cinnamon extract may possess potential nephrotoxicity and hepatotoxicity at dose higher than its recommended daily safe dose. Further study is needed to clarify the mechanism involved in its induction of liver and kidney injury.


Asunto(s)
Cinnamomum aromaticum , Extractos Vegetales/toxicidad , Animales , Femenino , Riñón/efectos de los fármacos , Riñón/patología , Hígado/efectos de los fármacos , Hígado/patología , Masculino , Pruebas de Mutagenicidad , Tamaño de los Órganos/efectos de los fármacos , Corteza de la Planta , Ratas Endogámicas F344 , Pruebas de Toxicidad Aguda , Pruebas de Toxicidad Subcrónica
6.
Regul Toxicol Pharmacol ; 92: 46-54, 2018 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-29108849

RESUMEN

Ecklonia cava (EC) is known to have antioxidant, anti-inflammatory, antidiabetic, and anticancer properties. Despite its wide use and beneficial properties, comprehensive toxicological information regarding EC extract is currently limited. Therefore, the purpose of this study was to investigate acute toxicity, subchronic toxicity, and genotoxicity of enzymatic EC extract according to test guidelines published by Organization for Economic Cooperation and Development. The acute oral LD50 values of this EC extract administered to rats and dogs were estimated to be more than 3000 mg/kg BW. In an oral 13-week toxicity study, changes in body weights of rats exposed to the EC extract up to 3000 mg/kg BW were found to be normal. In addition, repeated doses of EC extract failed to influence any systematic parameters of treatment-related toxic symptoms such as food/water consumption, mortality, urinalysis, hematology, serum biochemistry, organ weight, or histopathology. These results indicated that the no-observed-adverse-effect level for the EC extract was 3000 mg/kg/day for male and female rats. Data obtained from Ames test, chromosome aberration assay, and micronucleus assay indicated that EC extract was not mutagenic or clastogenic. Taken together, these results support the safety of enzymatic EC extract as a potential therapeutic for human consumption against various diseases.


Asunto(s)
Laminaria/química , Extractos Vegetales/efectos adversos , Administración Oral , Animales , Perros , Femenino , Masculino , Ratones , Ratones Endogámicos ICR , Pruebas de Mutagenicidad/métodos , Nivel sin Efectos Adversos Observados , Tamaño de los Órganos/efectos de los fármacos , Ratas , Ratas Sprague-Dawley , Pruebas de Toxicidad Aguda/métodos , Pruebas de Toxicidad Subcrónica/métodos
7.
BMC Infect Dis ; 17(1): 402, 2017 06 07.
Artículo en Inglés | MEDLINE | ID: mdl-28592263

RESUMEN

BACKGROUND: With the emergence of macrolide resistance, concerns about the efficacy of macrolides for the treatment of Mycoplasma pneumoniae (MP) pneumonia in children have been raised. This study aimed to determine the effect of macrolide resistance on the outcome of children who were hospitalized with MP pneumonia. METHODS: Between 2010 and 2015, we performed culture of MP from nasopharyngeal samples obtained from children who were hospitalized with pneumonia at five hospitals in Korea. Macrolide resistance was determined by the analysis of 23S rRNA gene transition and the minimal inhibitory concentrations of four macrolides. Medical records were reviewed to analyze the clinical response to treatment with macrolides. RESULTS: MP was detected in 116 (4.8%) of the 2436 children with pneumonia. MP pneumonia was prevalent in 2011 and 2015. Of the 116 patients with MP pneumonia, 82 (70.7%) were macrolide-resistant. There were no differences in the age distribution, total duration of fever, and chest x-ray patterns between the macrolide-susceptible and macrolide-resistant groups. After macrolide initiation, mean days to defervescence were longer in the macrolide-resistant group than in macrolide-susceptible group (5.7 days vs. 4.1 days, P = 0.021). However, logistic regression analysis revealed that the presence of extrapulmonary signs (P = 0.039), homogeneous lobar consolidation (P = 0.004), or parapneumonic effusion (P < 0.001) were associated with fever duration of ≥7 days after the initiation of macrolides, regardless of macrolide resistance. CONCLUSIONS: This study demonstrated that fever duration in MP pneumonia was determined by the radiologic findings of chest x-ray, not by the presence of macrolide resistance. The results highlight the need for future studies to assess therapeutic benefit from macrolides in the treatment of children with MP pneumonia.


Asunto(s)
Antibacterianos/uso terapéutico , Macrólidos/uso terapéutico , Mycoplasma pneumoniae/efectos de los fármacos , Neumonía por Mycoplasma/diagnóstico por imagen , Niño , Preescolar , Farmacorresistencia Bacteriana , Femenino , Fiebre , Hospitales , Humanos , Lactante , Masculino , Pruebas de Sensibilidad Microbiana , Nasofaringe/diagnóstico por imagen , Nasofaringe/microbiología , Neumonía por Mycoplasma/tratamiento farmacológico , Neumonía por Mycoplasma/microbiología , República de Corea , Rayos X
8.
Regul Toxicol Pharmacol ; 88: 87-95, 2017 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-28487065

RESUMEN

Artemisia capillaris (AC) has been used as an alternative therapy in obesity, atopic dermatitis, and liver diseases through several biological activity including anti-steatotic, antioxidant, and anti-inflammatory activities. Despite its ethnomedicinal benefits, no sufficient background information is available about the long-term safety and genotoxicity of the AC extract. Therefore, the present study was carried out to investigate the 13-week subchronic toxicity and genotoxicity of the AC extract according to the test guidelines published by the Organization for Economic Cooperation and Development. In the 13-week toxicity study using doses of 25, 74, 222, 667, and 2000 mg/kg body weight, oral administration of the AC extract in male and female rats did not result in any significant adverse effects in food/water consumption, body weight, mortality, hematology, serum biochemistry, organ weight and histopathology. Accordingly, the no-observed-adverse-effect level in rats of both genders was established for the AC extract at 2000 mg/kg/day, the highest dose level tested. In addition, the AC extract was not genotoxic in a battery of tests including Ames test, in vitro chromosome aberration assay and in vivo micronucleus assay. In conclusion, we demonstrated that the AC extract is considered as a safe traditional medicine for human consumption.


Asunto(s)
Artemisia/química , Extractos Vegetales/toxicidad , Administración Oral , Animales , Peso Corporal , Ingestión de Líquidos , Ingestión de Alimentos , Femenino , Masculino , Pruebas de Micronúcleos , Nivel sin Efectos Adversos Observados , Tamaño de los Órganos , Extractos Vegetales/administración & dosificación , Ratas , Ratas Sprague-Dawley , Pruebas de Toxicidad Subcrónica
9.
Vaccine ; 34(40): 4771-6, 2016 09 14.
Artículo en Inglés | MEDLINE | ID: mdl-27546875

RESUMEN

BACKGROUND: This study was performed to assess the serotype distribution and antibiotic nonsusceptibility of pneumococcal carriage isolates from children in Korea following the introduction of extended-valency pneumococcal conjugate vaccines (PCVs). METHODS: From April to June 2014, nasopharyngeal swabs were collected from children who were attending daycare centers in Korea. The collection was conducted in accordance with the World Health Organization Pneumococcal Carriage Working Group standards. Isolates were identified based on colony morphology, the presence of alpha-hemolysis, and inhibition by optochin test. Serotype was determined by Quellung reaction and sequencing analysis (for serogroup 6). The E-test was performed to determine antibiotic susceptibility. RESULTS: A total of 267 pneumococcal isolates were collected from 734 children. Non-PCV13 serotypes accounted for 88.3% and 23A (12.6%), 15B (10.4%), and 15C (9.5%) were most common. Younger age was associated with higher carriage (65.6% vs. 31.2%, P<0.001), while completion of PCV vaccination was associated with lower carriage caused by PCV13 serotypes (7.4% vs. 20.8%, P=0.007). Overall, nonsusceptibility rates were 86.0% to penicillin and 90.5% to erythromycin, with a multidrug resistance rate of 81.5%. Among penicillin-nonsusceptible isolates, those caused by PCV13 serotypes were 11% and non-PCV13 serotypes were 89%. Frequent non-PCV13 serotypes (23A, 15B, and 15C) were all nonsusceptible to both penicillin and erythromycin except one. CONCLUSION: High rates of carriage caused by non-PCV13 serotypes such as 23A, 15B, and 15C that show nonsusceptibilities to penicillin and erythromycin were noted following the introduction of extended-valency PCVs in Korea.


Asunto(s)
Portador Sano/epidemiología , Infecciones Neumocócicas/prevención & control , Vacunas Neumococicas/uso terapéutico , Portador Sano/microbiología , Preescolar , Farmacorresistencia Bacteriana Múltiple , Eritromicina , Femenino , Vacuna Neumocócica Conjugada Heptavalente/uso terapéutico , Humanos , Lactante , Masculino , Pruebas de Sensibilidad Microbiana , Nasofaringe/microbiología , Penicilinas , República de Corea/epidemiología , Serogrupo , Streptococcus pneumoniae/efectos de los fármacos
10.
Regul Toxicol Pharmacol ; 73(1): 303-10, 2015 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-26188118

RESUMEN

The rhizomes of Cimicifuga species, including Cimicifuga heracleifolia (CH), have been widely used as antipyretic, analgesic, and anti-inflammatory agents in oriental countries. However, information regarding its toxicity, especially long-term toxicity and genotoxicity, is limited. Therefore, we performed the subchronic toxicity and genotoxicity assays of the CH extract in accordance with the test guidelines published by the Organization for Economic Cooperation and Development. In a 13-week repeat-dose oral toxicity study, the CH extract did not influence body weight, food/water consumption, mortality, clinical signs, and urinalysis throughout the study. Noteworthy, the CH extract groups exhibited increased liver weights along with serum alanine transaminase activity rise at doses of 667 and 2000 mg/kg in females. No-observed-adverse-effect-level of the CH extract administered orally was concluded to be 2000 mg/kg body weight/day for male rats and 222 mg/kg body weight/day for female rats. The CH extract did not exert a mutagenic or clastogenic effect in Ames test, in vitro chromosome aberration assay and in vivo micronucleus assay. Overall findings of the subchronic toxicity study indicate for the first time that the CH extract may possess hepatotoxic potential in female rats, suggesting that further mechanistic studies should be performed to have more conclusive results on hepatotoxic potential of the CH extract.


Asunto(s)
Cimicifuga/efectos adversos , Extractos Vegetales/efectos adversos , Animales , Peso Corporal/efectos de los fármacos , Aberraciones Cromosómicas/inducido químicamente , Relación Dosis-Respuesta a Droga , Femenino , Masculino , Pruebas de Micronúcleos/métodos , Pruebas de Mutagenicidad/métodos , Nivel sin Efectos Adversos Observados , Tamaño de los Órganos/efectos de los fármacos , Ratas , Ratas Endogámicas F344 , Pruebas de Toxicidad Subcrónica/métodos
11.
Regul Toxicol Pharmacol ; 70(2): 527-34, 2014 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-25223566

RESUMEN

Paecilomyces tenuipes is entomogenous fungus that is called snow-flake Dongchunghacho in Korea. Although it is widely used in traditional medicines, its safety has not yet been comprehensively investigated. Therefore, the aim of this study was to evaluate the genotoxicity, acute and subchronic toxicity of P. tenuipes. The acute oral LD50 of P. tenuipes extract in rats was estimated to be greater than 2000mg/kg of body weight. In the subchronic study, the oral treatment of rats with 500, 1000 or 2000mg/kg P. tenuipes extract daily for 13weeks did not induce any dose-related changes (body weight, food consumption, clinical observation, urinalysis, hematology, clinical chemistry and organ weight). In contrast, histopathological observation revealed that P. tenuipes extract induced karyomegaly in outer medulla of kidney in all treated rats. Importantly, P. tenuipes extract exerted the mutagenic potential in Ames assay. Since karyomegalic alterations have been known to be associated with carcinogenicity, our finding on the mutagenicity of P. tenuipes extract supports the possibility on the potential involvement of P. tenuipes in carcinogenicity at least partially. In conclusion, the subchronic oral exposure of P. tenuipes may induce kidney abnormality at the concentration higher than 500mg/kg body weight, although further studies using other animal models are needed to identify the toxicity of P. tenuipes.


Asunto(s)
Factores Biológicos/efectos adversos , Riñón/efectos de los fármacos , Medicina Tradicional/efectos adversos , Mutágenos/efectos adversos , Paecilomyces/metabolismo , Animales , Peso Corporal/efectos de los fármacos , Relación Dosis-Respuesta a Droga , Femenino , Masculino , Pruebas de Mutagenicidad/métodos , Tamaño de los Órganos/efectos de los fármacos , Ratas , Ratas Sprague-Dawley , República de Corea , Pruebas de Toxicidad Subcrónica/métodos
12.
Clin Mol Hepatol ; 19(3): 305-8, 2013 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-24133669

RESUMEN

Autoimmune hepatitis (AIH) has been reported in association with Sjögren's syndrome (SS). Drug-induced AIH has been rarely reported. A rare case of the co-development of AIH and SS in a 53-year-old woman after the consumption of herbal medicines is described. After admission, the patient complained of dryness in her mouth, and she was subsequently diagnosed with SS, which had not been detected previously. The patient's bilirubin and aminotransferase levels initially decreased following conservative management; however, they later began to progressively increase. A diagnosis of AIH was made based on the scoring system proposed by the International Autoimmune Hepatitis Group. The patient was administered a combination of prednisolone and azathioprine, and the results of follow-up liver-function tests were found to be within the normal range. This is an unusual case of AIH and SS triggered simultaneously by the administration of herbal medicines.


Asunto(s)
Hepatitis Autoinmune/diagnóstico , Medicina de Hierbas , Síndrome de Sjögren/diagnóstico , Alanina Transaminasa/sangre , Aspartato Aminotransferasas/sangre , Azatioprina/uso terapéutico , Bilirrubina/sangre , Femenino , Hepatitis Autoinmune/complicaciones , Hepatitis Autoinmune/tratamiento farmacológico , Humanos , Hígado/patología , Pruebas de Función Hepática , Persona de Mediana Edad , Prednisolona/uso terapéutico , Síndrome de Sjögren/complicaciones , Síndrome de Sjögren/tratamiento farmacológico
13.
Biosci Biotechnol Biochem ; 74(10): 2029-35, 2010.
Artículo en Inglés | MEDLINE | ID: mdl-20944422

RESUMEN

The purpose of this study was to determine whether the Laurus nobilis chloroform fraction (LNCF) protects against cerebral ischemia neuronal damage. Human neuroblastoma SH-SY5Y cells and brain slices from rats were subjected to oxygen and glucose deprivation (OGD), followed by reoxgenation with and without LNCF. The viabilities of SH-SY5Y cells and brain slices from the rats were 58.5±4.9% and 79.7±5.9% in the group subjected to OGD, and 80.4±0.4% and 97.2±1.9% at 4 µg/ml of LNCF, respectively. LNCF also significantly inhibited death-associated protein kinase (DAPK) dephosphorylation. Pretreatment with LNCF at 4 mg/kg significantly decreased infarct size by 79% of vehicle control in the middle cerebral artery occlusion (MCAO) in vivo model. LNCF is a neuroprotective drug candidate against cerebral ischemia neuronal damage.


Asunto(s)
Muerte Celular/efectos de los fármacos , Cloroformo/química , Glucosa/deficiencia , Laurus/química , Neuronas/efectos de los fármacos , Oxígeno/metabolismo , Extractos Vegetales/farmacología , Animales , Proteínas Reguladoras de la Apoptosis/metabolismo , Infarto Encefálico/metabolismo , Infarto Encefálico/patología , Infarto Encefálico/prevención & control , Proteínas Quinasas Dependientes de Calcio-Calmodulina/metabolismo , Línea Celular Tumoral , Supervivencia Celular/efectos de los fármacos , Proteínas Quinasas Asociadas a Muerte Celular , Activación Enzimática/efectos de los fármacos , Regulación Enzimológica de la Expresión Génica/efectos de los fármacos , Hipocampo/efectos de los fármacos , Hipocampo/metabolismo , Hipocampo/patología , Humanos , Masculino , Neuronas/metabolismo , Neuronas/patología , Fármacos Neuroprotectores/aislamiento & purificación , Fármacos Neuroprotectores/farmacología , Fosfoproteínas/metabolismo , Extractos Vegetales/aislamiento & purificación , Ratas , Ratas Sprague-Dawley
15.
Plast Reconstr Surg ; 121(4): 179e-185e, 2008 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-18349597

RESUMEN

BACKGROUND: Despite the increasing interest in mesotherapy as an alternative method for body contouring, there are few reports of its safety, efficacy, and mechanism of action. A clinical examination was performed to evaluate the efficacy of mesotherapy for body contouring. METHODS: Twenty women were enrolled in this prospective, case-controlled study over a 12-week period. The authors injected a mixed solution (i.e., aminophylline, buflomedil, and lidocaine) into the superficial dermis of the medial aspect of one thigh weekly using a mechanical delivery gun. There was no treatment to the other thigh. The change in the fat level was evaluated by measuring the girth of the thighs and by computed tomographic scanning. The lipid profiles were checked to determine the effect of mesotherapy on lipid metabolism, and questionnaires were used to determine the satisfaction rate of the patients. RESULTS: The loss of thigh girth on the treated side was not significantly different from that of the untreated side. The computed tomographic scans showed no statistically significant difference in the cross-sectional area or thickness of the fat layer between each group. There were no statistically significant changes in the lipid profiles except for the triglyceride level. A questionnaire asking about the effect of mesotherapy indicated poor patient satisfaction. CONCLUSION: Mesotherapy is not an effective alternative treatment modality for body contouring.


Asunto(s)
Técnicas Cosméticas , Adulto , Estudios de Casos y Controles , Femenino , Humanos , Satisfacción del Paciente , Estudios Prospectivos , Muslo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA